Abstract
Strategies to minimize immune-suppressive medications after liver transplantation are limited by allograft rejection. Biopsy of liver is the current standard of care in diagnosing rejection. However, it adds to physical and economic burden to the patient and has diagnostic limitations. In this review, we aim to highlight the different biomarkers to predict and diagnose acute rejection. We also aim to explore recent advances in molecular diagnostics to improve the diagnostic yield of liver biopsies.
Original language | English (US) |
---|---|
Pages (from-to) | 139-148 |
Number of pages | 10 |
Journal | Journal of Clinical and Experimental Hepatology |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2023 |
Externally published | Yes |
Keywords
- Liver transplantation
- MMDX
- biomarker
- donor-derived cell-free DNA
- immune-suppression
- micro-RNA
- molecular diagnosis
- nano-string
- rejection
ASJC Scopus subject areas
- Hepatology